Proven expertise in a new structure: Adamant Biomedical Investment and Bellevue Asset Management were officially merged on January 1, 2015, thus strengthening their position as a market leader for healthcare sector investments. The team headed by Dr. Cyrill Zimmermann that has served you in the past will continue to manage Adamant’s previously existing range of products and it has also assumed responsibility for the healthcare investment funds and mandates offered by Bellevue. The Adamant brand will be retained at the product level. 

 

News
Funds Healthcare
NAV
BB Adamant Biotech B-USD
420.51
BB Adamant Medtech B-EUR
321.70
BB Adamant Global Medtech und Services AA-CHF
1,771.58
BB Adamant Global Biotech AA-CHF
2,714.10
BB Adamant Global Generika AA-CHF
1,413.79
BB Adamant Global Healthcare Index T-CHF
2,048.66
Lacuna - BB Adamant Asia Pacific Health P-EUR
217.27
Lacuna - BB Adamant Global Healthcare P-EUR
373.00
NAV/Performance